close

Background

EmavundleniEmavundleni  Research Centre  is a branch of the Desmond Tutu HIV Centre.

There are 2 core beliefs that drive all activities done at Emavundleni, namely:

  • That excellent research leads to effective evidence based clinical guidelines, which lead to better patient outcomes and more effective health policy.
  • HIV prevention is crucial to eventually beating HIV.

Since its inception in 2006, the research centre based in Crossroads, has conducted research into development of strategies for HIV and HPV prevention and provided a few essential health services to the population in the surrounding Nyanga district.

These activities include:

  • Adult studies involving randomized controlled trials and observational studies to develop HIV vaccines that elicit a cell-mediated immune response against HIV, and HIV vaccines that elicit a broadly neutralizing antibody response against HIV. These were performed in partnership with sponsors including HVTN, and IAVI.
  • Adult randomized controlled trials researching other HIV prevention strategies including oral and vaginally administered HIV pre-exposure prophylaxis (PrEP), in partnership with MTN and HPTN.
  • Adolescent studies including sponsor driven randomized controlled trials to develop HPV and TB vaccines in partnership with Merck and AERAS.
  • Investigator driven observational studies to determine factors that affect the acceptability of and adherence to vaccines.
  • Provision of essential services to the Nyanga community including provision of HIV voluntary counselling and testing, STD treatment and oral, injectable and long acting reversible contraception.

Current Trials

Sponsor: MTN
DTHF PI: Prof Linda-Gail Bekker
Site: Emavundleni
Status: Recruiting

MTN 016

HIV Prevention Agent Pregnancy Exposure Registry: EMBRACE (Evaluation of Maternal and Baby Outcome Registry After Chemoprophylactic Exposure) study

More Info: Click Here

Sponsor: MERCK
DTHF PI: Dr Surita Roux
Site: Emavundleni
Status: Active - Not Recruiting

V503-010

A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of a 2-dose regimen of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, administered in Preadolescents and Adolescents (9 to 14 year olds) with a Comparison to Young Women (16 to 26 year olds)

More Info: Click Here

Sponsor: MERCK
DTHF PI: Prof Linda-Gail Bekker
Site: Groote Schuur CTU
Status: Active - Not Recruiting

V503-002

Phase III Clinical Trial to Study the Immunogenicity, Tolerability,vand Manufacturing Consistency of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (9 to 15 year olds) with a Comparison to Young Women (16 to 26 year olds)

More Info: Click Here

Sponsor: MTN
DTHF PI: Prof Linda-Gail Bekker
Site: Emavundleni
Status: Recruiting

MTN 015

An Observational Cohort Study of Women following HIV-1 Seroconversion in Microbicide Trials

More Info: Click Here

Sponsor: HVTN
DTHF PI: Prof Linda-Gail Bekker
Site: Emavundleni
Status: Recruiting

HVTN 910

A protocol to assess the persistence of HIV vaccine-induced seropositivity in participants who received vaccine in DAIDS-funded preventive HIV vaccine trials

More Info: Click Here

Sponsor: MTN
DTHF PI: Prof Linda-Gail Bekker
Site: Emavundleni
Status: Active - Not Recruiting

MTN 020

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase 3 Safety and Effectiveness Trial of a Vaginal Matrix Ring Containing Dapivirine for the Prevention of HIV-1 Infection in Women

More Info: Click Here

Sponsor: HVTN
DTHF PI: Prof Linda-Gail Bekker
Site: Emavundleni
Status: Recruiting

HVTN 802

A descriptive and observational study of the effectiveness of potent antiretroviral therapy in HIV-1–infected persons who become HIV infected during the course of HIV-1 vaccine efficacy trials

Sponsor: HVTN
DTHF PI: Prof Linda-Gail Bekker
Site: Emavundleni
Status: Recruiting

HVTN 404

Long-term follow-up of HIV-1 infection in participants who become infected after enrollment in early-phase (phase 1 and 2a) HIV vaccine protocols or HIV vaccine preparedness cohorts

Sponsor: HVTN
DTHF PI: Prof Linda-Gail Bekker
Site: Emavundleni
Status: Active - Not Recruiting

HVTN 097

A phase 1b randomized double blind placebo controlled clinical trial to evaluate the safety and immunogenicity of the vaccine regimen ALVAC-HIV (vCP1521) followed by AIDSVAX® B/E in healthy, HIV-1 uninfected adult participants in South Africa

More Info: Click Here

People

Emavundleni-Staff-Group

Performing the activities mentioned would not be possible without effective teamwork by many team members. We are proud of our tightly knit team, which includes:

  • Our Principal Investigator, Professor Linda-Gail Bekker who is responsible for protocol development, overseeing all research activites and dissemination of key findings generated by the research.
  • Our Project Manager, Dr Surita Roux, who manages the operational aspects of Emavundleni, and is involved in most key research activities.
  • A clinical team trained in both clinical management of participants and clinical trials, consisting of investigators, study co-ordinators and research nurses, supervised by Dr Danielle Crida.
  • The pharmacy team headed by Melanie Maclachlan responsible for dispensing investigational product and dispensing non study medication, and managing the pharmacy.
  • Our counselling team which assists with informed consent, provides risk reduction and study specific counselling, and educates participants about details of research studies prior to them being screened.
  • Our community team headed by Ntando Yola, that partners with community members and stakeholders, educates the community about HIV,STDs,TB and research studies, and recruits potential participants..
  • Our data team headed by Litha Gogo responsible for ensuring the delivery of high quality data.
  • Our laboratory team headed by Dyan Belonje responsible for management of all study and non-study related laboratory tests, and for ensuring Good Clinical Laboratory Practise.
  • Administrative and support staff including receptionists, an office administrator, regulatory officer and finance manager
  • Caretakers and Cleaning staff that keep Emavundleni clean and in a condition consistent with running a clinic.
Linda-Gail Bekker

Chief Operating Officer

Litha Gogo

Data Manager

Avril Masters

Study Coordinator

Danielle Crida

Senior Medical Officer

Doerieyah Reynolds

Study Coordinator

Dorothie Van de Vent

Study Coordinator

Elaine Sebastian

Study Coordinator

Ntando Yola

Community Liason Officer

Wendy Wiemers

Finance Manager

COMMUNITY ENGAGEMENT

Communities are central to effective conduct and success of HIV and TB biomedical research. In distinguishing this role the Emavundleni Centre invests a lot of time, resources and capacity in constant consultation and two-way engagement with the community exhausting a variety of mechanisms. This is to ensure that communities are a partner with a strong voice that will be hard to ignore in the conduct and eventual success of HIV and TB prevention research. A complement of staff members is dedicated into engaging with the community through a Community Advisory Board (CAB), as well as partnerships with a range of community leadership platforms, organizations that are community based, government and non-governmental. In meeting with community HIV and TB needs concurrent partnerships with service provider’s forms part of our deliberate focus. This is all in keeping with promotion of ethical conduct in trials and ensuring of Good Participatory Practice principles.

Ema-9141 Ema-9142

The community engagement team activities in close consultation primarily with the CAB include general health, HIV, TB and related diseases awareness education. In reaching a broader community, presentations to community organized and spontaneous groups, workshops, public awareness events are organized continuously. This provides amongst other opportunities an adequate understanding on what the needs of the communities are in relation to research and how to best co-facilitate partnerships that work to achieve an end to AIDS and TB.

Awareness events are organized annually alongside major health calendar events commemorated to give attention to a number of HIV, TB and related structural factors in South Africa. They further present prospects for mutual support and benefit in community health work, research and development.

These include:
– February – Sexually Transmitted Infection, Condom and Sexual Health weeks respectively.
– March – TB awareness month.
– May 18 – World AIDS Vaccine Day
– June – Youth month
– August – Women’s month
– December 1st – World AIDS day.

Contact

Emavundleni Project Manager:

Dr Surita Roux
Email: surita.roux@hiv-research.org.za
Telephone: (+27) 21 386 0053
Facsimile:    (+27) 21 386 0054

Physical address
Emavundleni Research Centre
14 Sonwabile Drive
Old Crossroads
Nyanga , Cape Town 7750

Postal address
Emavundleni
PO Box 13801
Mowbray
Cape Town 7705